Takeda Pharmaceutical Co Ltd: 6-K Filing Summary
Business Context and Reporting Period
This Form 6-K filing reports the Earnings Report (Kessan Tanshin) for the six-month period ended September 30, 2025, filed on October 30, 2025. Takeda Pharmaceutical Company Limited operates as a single operating segment focused on the research, development, manufacturing, and marketing of pharmaceutical products. The results are presented under International Financial Reporting Standards (IFRS).
Key Financial Metrics
| Metric | Six Months Ended Sep 30, 2025 | Six Months Ended Sep 30, 2024 | Change (AER) |
|---|---|---|---|
| Revenue | JPY 2,219.5 billion | JPY 2,384.0 billion | -6.9% |
| Operating Profit | JPY 253.6 billion | JPY 350.6 billion | -27.7% |
| Profit Before Tax | JPY 178.8 billion | JPY 256.0 billion | -30.1% |
| Net Profit (Attributable to Owners) | JPY 112.4 billion | JPY 187.3 billion | -40.0% |
| Basic EPS | JPY 71.57 | JPY 118.85 | -39.8% |
| Core Operating Profit | JPY 639.2 billion | JPY 719.9 billion | -11.2% |
| Core EPS | JPY 279 | JPY 310 | -10.0% |
Balance Sheet & Liquidity: Total assets increased to JPY 14,470.3 billion. Cash and cash equivalents rose to JPY 681.5 billion. Total bonds and loans stood at JPY 4,645.3 billion. The equity ratio attributable to owners of the company was 49.3%.
Cash Flow: Net cash from operating activities was JPY 593.7 billion (up JPY 142.4 billion YoY). Net cash used in investing activities was JPY 81.3 billion. Net cash used in financing activities was JPY 226.9 billion.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 6.9% (Actual Exchange Rate) primarily due to a significant drop in the Neuroscience segment (-34.5%) driven by generic erosion of VYVANSE in the U.S., and unfavorable foreign exchange rates. The U.S. region saw a 12.5% revenue decline.
- Profitability Pressure: Operating profit fell 27.7% due to lower revenue, higher amortization and impairment losses (JPY 336.8 billion), and unfavorable product mix. Impairment losses increased by JPY 48.3 billion, including JPY 58.2 billion related to the discontinuation of the gamma delta T-cell therapy platform.
- Cost Management: R&D expenses decreased 11.2% due to program terminations and efficiency programs. SG&A expenses decreased 5.4% due to yen appreciation and cost savings.
- Segment Performance: While Neuroscience and Vaccines declined, Gastroenterology (GI), Rare Diseases, Plasma-Derived Therapies (PDT), and Oncology showed slight growth on a Constant Exchange Rate (CER) basis.
Guidance, Outlook, and Risks
Revised Full-Year Forecast (FY Ending March 31, 2026): Management has revised its full-year outlook downward from the May 2025 announcement.
- Revenue: Revised to JPY 4,500.0 billion (down 0.7% from original forecast), reflecting steeper VYVANSE declines and revised ENTYVIO forecasts.
- Operating Profit: Revised to JPY 400.0 billion (down 15.8% from original), impacted by product mix, FX headwinds, and higher impairment forecasts.
- Net Profit: Revised to JPY 153.0 billion (down 32.9% from original).
- EPS: Revised to JPY 97.14 (down 32.9% from original).
Management Guidance (CER Basis):
- Core Revenue: Broadly Flat
- Core Operating Profit: Low-single-digit % decline
- Core EPS: Low-single-digit % decline
Risks and Contingencies:
- Generic Erosion: Continued impact on VYVANSE and RESOLOR/MOTEGRITY.
- Regulatory/Policy: Impacts from Medicare Part D redesign and 340B program expansion in the U.S.
- FX Volatility: Fluctuations in foreign exchange rates significantly impact reported results.
- Tariffs: Assumptions include potential 15% tariffs on pharmaceutical imports to the U.S. from EU and Japan, though impact is currently expected to be immaterial.
Dividends: Interim dividend of JPY 100 per share approved for payment starting December 1, 2025. Annual dividend projection remains JPY 200 per share.
Investor Verification Checklist
- VYVANSE Trajectory: Verify the sustainability of the 35% CER decline in VYVANSE sales and the impact on the Neuroscience segment's long-term revenue.
- Impairment Charges: Review the details of the JPY 58.2 billion impairment on the gamma delta T-cell therapy platform and assess if further pipeline cuts are likely.
- FX Sensitivity: Analyze the divergence between Actual Exchange Rate (AER) and Constant Exchange Rate (CER) performance to understand the true operational trend versus currency impact.
- Debt Structure: Monitor the JPY 4.6 trillion debt load, specifically the maturity profile of the new USD and JPY bonds issued in mid-2025.
- Innovent Collaboration: Assess the strategic value and financial impact of the new USD 1.2 billion upfront payment and collaboration with Innovent Biologics for solid tumor medicines.